METABOLIC DYSFUNCTION-ASSOCIATED FATTY LIVER: WHAT YOU NEED TO KNOW?
WHAT IS METABOLIC DYSFUNCTION-ASSOCIATED FATTY LIVER DISEASE?
Fatty liver, or metabolic dysfunction-associated steatotic liver disease (MASLD), is a condition in which fat accumulates in liver cells due to metabolic dysfunction.
If fat accumulation is intense and prolonged, this process can lead to liver inflammation, a condition defined as metabolic dysfunction-associated steatohepatitis (MASH).

WHAT IS THE GLOBAL PREVALENCE OF THIS CONDITION?
Metabolic dysfunction-associated steatotic liver disease is the most common liver disease in the Western industrialized world. Research estimates that globally, this condition is present in about 30% of the population, while in North America, the prevalence is even higher, reaching up to 44% of the population.
WHAT CAUSES FATTY LIVER AND WHAT CONDITIONS IS IT ASSOCIATED WITH?
The exact causes of fatty liver disease are not entirely known or clearly defined. However, it has been established that this condition is more commonly found in patients with metabolic syndrome, which includes:
- Excess body weight: Body mass index (BMI) > 25
- Insulin resistance (prediabetes and diabetes)
- Elevated blood lipids (cholesterol and/or triglycerides)
- High blood pressure
WHAT SYMPTOMS DOES FATTY LIVER CAUSE?
Patients with fatty liver typically have no symptoms, although liver enzymes (AST, ALT) may sometimes be slightly elevated. Patients with steatohepatitis are also usually asymptomatic, although due to the inflammatory process, some may experience mild and dull pain under the right rib cage, fatigue, or weakness, with elevated liver enzymes.
HOW IS THIS CONDITION DIAGNOSED?
- Abdominal Ultrasound: If fat accumulation affects at least 20% of the liver tissue, fatty liver can be easily diagnosed through ultrasound examination.
- Magnetic Resonance Imaging (MRI): A method that more precisely detects and quantifies fat accumulation in the liver.
- Liver Biopsy for Steatohepatitis: While elevated liver enzymes, leukocytes, and CRP levels suggest steatohepatitis, a definitive diagnosis requires a histopathological analysis of a small liver tissue sample obtained through biopsy.
- Transient Elastography / FibroScan: Methods that assess liver stiffness to evaluate the presence of liver fibrosis, which can result from prolonged fatty liver disease.
HOW IS METABOLIC DYSFUNCTION-ASSOCIATED FATTY LIVER TREATED?
There are no specific therapeutic measures targeting the liver fat accumulation process itself. Treatment focuses on addressing the underlying and/or associated conditions believed to contribute to the development and progression of the disease. Such measures include:
- Weight management: A key therapeutic measure that reduces inflammation, improves metabolic dysfunction, and lowers cardiovascular risk.
To achieve liver fat reduction, at least 5% of body weight should be lost. For patients with steatohepatitis or liver fibrosis, weight loss of at least 7-10% is recommended. Weight loss should not exceed 1 kg per week.
- Proper blood sugar regulation for diabetic patients, as advised by an endocrinologist.
- Lipid-lowering treatment for patients who do not achieve adequate cholesterol/triglyceride control through a low-fat diet.
- Blood pressure management for patients with hypertension.
- Engaging in appropriate physical activity based on age and body constitution.
- Following a healthy diet, such as the Mediterranean diet.
- Avoiding alcohol consumption.
ADDITIONAL THERAPEUTIC MEASURES FOR SELECTED PATIENT GROUPS
- Vitamin E: In patients with severe steatohepatitis who do not have diabetes, Vitamin E may help control liver inflammation. However, due to possible side effects, it should only be taken under medical supervision.
- Hepatitis A and B Vaccination.
WHAT IS THE COURSE OF THIS DISEASE AND WHAT ARE THE MAIN RISKS OF METABOLIC DYSFUNCTION-ASSOCIATED FATTY LIVER?
- Liver Fibrosis/Cirrhosis: Most patients with fatty liver will not experience severe liver disorders. However, in some patients with steatohepatitis, if inflammation is not controlled, the disease can progress and cause liver fibrosis or cirrhosis, leading to irreversible liver damage and impaired liver function.
- Liver Cancer: The presence of metabolic dysfunction-associated steatosis, especially steatohepatitis or liver cirrhosis, is a risk factor for liver cancer development. According to medical literature, hepatocellular carcinoma occurs in approximately 1-2% of patients with MASH-associated cirrhosis, which is why regular preventive ultrasound screenings (typically every six months) with or without alpha-fetoprotein (AFP) measurement are recommended.
Scientific Associate Dr. Elena Curakova Ristovska
Internist Gastroenterologist-Hepatologist